España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Catalent
CTLT
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$58.74
-0.04
-0.07%
Pre-Market: 4:16 PM EDT
Get Report
Comment
Catalent (CTLT) Forecast
News
Earnings
Catalent (CTLT) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Catalent (NYSE:CTLT) Stock
Catalent Stock (NYSE: CTLT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, November 05, 2024
Catalent Q1 2025 Adj EPS $(0.13) May Not Be C...
Benzinga Newsdesk
Wednesday, October 23, 2024
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Vandana Singh
Monday, October 21, 2024
Catalent's CEO Confirms Leadership Continuity...
Benzinga Newsdesk
Friday, October 18, 2024
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Vandana Singh
Tuesday, October 15, 2024
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Avi Kapoor
Monday, October 14, 2024
Catalent Agrees To Sell Its Oral Solids Devel...
Benzinga Newsdesk
Thursday, October 10, 2024
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Vandana Singh
'Warren urges FTC to probe deal that would gi...
Benzinga Newsdesk
Tuesday, September 24, 2024
Baird Downgrades Catalent to Neutral, Maintai...
Benzinga Newsdesk
Tuesday, September 03, 2024
William Blair Reiterates Market Perform on Ca...
Benzinga Newsdesk
Thursday, August 29, 2024
Catalent Q4 2024 Adj. EPS $0.65 Beats $0.47 E...
Benzinga Newsdesk
Thursday, August 08, 2024
Lilly Executive Says Concord Manufacturing Si...
Benzinga Newsdesk
Wednesday, August 07, 2024
Novo Nordisk CFO Said In Active Dialogue With...
Benzinga Newsdesk
Wednesday, July 17, 2024
Catalent Expands Its Facility Capabilities in Germany
Zacks
Tuesday, July 16, 2024
Catalent Completes $25M Upgrade To Schorndorf...
Benzinga Newsdesk
Thursday, July 11, 2024
RBC Capital Reiterates Sector Perform on Cata...
Benzinga Newsdesk
Friday, June 28, 2024
Barclays Maintains Equal-Weight on Catalent, ...
Benzinga Newsdesk
Friday, June 21, 2024
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Vandana Singh
Wednesday, May 29, 2024
Catalent Stockholders Approve Acquisition By ...
Benzinga Newsdesk
Friday, May 24, 2024
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Piero Cingari
Wednesday, May 08, 2024
Catalent Q3 EPS $(0.06) Misses $0.21 Estimate...
Benzinga Newsdesk
Siren Biotechnology And Catalent Partner To M...
Benzinga Newsdesk
Thursday, May 02, 2024
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Benzinga Neuro
Friday, April 12, 2024
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Vandana Singh
Thursday, April 04, 2024
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
Benzinga Insights
Stephens & Co. Reiterates Equal-Weight on Cat...
Benzinga Newsdesk
Tuesday, April 02, 2024
Invenra To Collaborate With Catalent To Co-Di...
Benzinga Newsdesk
Friday, March 08, 2024
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
Vandana Singh
Thursday, March 07, 2024
Novo Nordisk CFO Says If Catalent Deal Does N...
Benzinga Newsdesk
Novo Nordisk CFO Says If Catalent Deal Does N...
Benzinga Newsdesk
Wednesday, March 06, 2024
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
Vandana Singh
Friday, March 01, 2024
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
Piero Cingari
Thursday, February 29, 2024
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Piero Cingari
Wednesday, February 28, 2024
(CTLT) - Analyzing Catalent's Short Interest
Benzinga Insights
Monday, February 26, 2024
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Neil Dennis
Tuesday, February 20, 2024
In-Depth Examination Of 5 Analyst Recommendations For Catalent
Benzinga Insights
RBC Capital Reiterates Sector Perform on Cata...
Benzinga Newsdesk
Wednesday, February 14, 2024
Catalent Says During 3 Months Ended Dec 31, 2...
Benzinga Newsdesk
Catalent Says Upon Termination Of Merger With...
Benzinga Newsdesk
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
Piero Cingari
Monday, February 12, 2024
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
Vandana Singh
Friday, February 09, 2024
Catalent Q2 Adjusted EPS $(0.24) May Not Be C...
Benzinga Newsdesk
US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March
Shanthi Rexaline
Earnings Scheduled For February 9, 2024
Benzinga Insights
Thursday, February 08, 2024
The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry
Piero Cingari
Earnings Outlook For Catalent
Benzinga Insights
Wednesday, February 07, 2024
Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns
Vandana Singh
European Drugs Regulator EMA Says It Will Ass...
Benzinga Newsdesk
Tuesday, February 06, 2024
Lilly Exec Says "Intend On Holding Catalent A...
Benzinga Newsdesk
Catalent Analysts Raise Their Forecasts Following Acquisition News
Avi Kapoor
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
